Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration
02/07/2026 02:33
BRIEF-Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration July 2 (Reuters) - Abbisko Cayman Ltd 2256.HK:
ABBISKO THERAPEUTICS AND ASTRAZENECA ENTER A STRATEGIC COLLABORATION
CO AND ASTRAZENECA ENTER STRATEGIC COLLABORATION FOR LUMIPODLIN CLINICAL TRIAL IN NSCLC
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration